Predictors of first treatment discontinuation.

<p>Abbreviations: n: number, HR: Hazard Ratio, CI: Confidence Interval, IFN: Interferon, IM: intramuscular, SC: Subcutaneous, GA: Glatiramer Acetate, EDSS: Expanded Disability Status Scale.</p><p>Treatment initiations n = 760 excluding Natalizumab (n = 11).</p>α<p>Cox Proportional Hazards Regression.</p><p>Multivariable Cox Proportional Hazards model was adjusted for sex, disease duration, age at treatment start, treatment and EDSS.</p><p># Proportional hazards test: p = 0.3747.</p>*<p>No EDSS score available at the time of treatment start.</p

Proportion of patients class switching from first to second IFNβ preparation.

<p>Proportion of patients class switching from first to second IFNβ preparation.</p

Baseline Patient Characteristics at subsequent treatment initiation.

<p>Abbreviations: n, number; y, years; SD, standard deviation; IQR, interquartile range; EDSS, Expanded Disability Status Scale.</p>α<p>Pearson χ² test.</p>β<p>One-way ANOVA with Bonferroni’s post hoc test.</p>γ<p>Kruskal-Wallis rank sum test.</p

Kaplan-Meier survival estimates for treatment discontinuation (Subsequent DMT).

<p>A: Treatment discontinuation by DMT. This figure demonstrates that patients prescribed Natalizumab as a subsequent DMT discontinue treatment at a significantly slower rate than those prescribed Glatiramer Acetate or any of the IFNβ preparations (adjusted Cox Proportional Hazards Regression, p = 0.000). B: Treatment discontinuation by EDSS. This figure demonstrates that patients with EDSS 1–2.5 (p = 0.046), EDSS 3–5.5 (p = 0.013) and EDSS ≥6 (p = 0.008) discontinue treatment at a significantly greater rate than those with EDSS 0 (adjusted Cox Proportional Hazards Regression).</p

Sex ratio, percent of relapsing onset, mean age at onset and mean time from onset to diagnosis by birth decades in female (F) and male (M) MS patients.

*<p> <i>15996 pts; p-value for trend 0.032; ^Λ14543 pts; °11998 pts; § p&lt;0.05 sex M vs. F.</i></p><p>RR = Relapsing remitting; PP = Primary progressive.</p

Sex ratio, percent of relapsing onset, mean age at onset and mean time from onset to diagnosis by birth decades and latitude in female (F) and male (M) MS patients.

<p>RR = Relapsing remitting; PP = Primary progressive.</p

Plot of gender ratio by six birth decades in MS patients stratified by Latitude.

<p> <i>p-value for trend *0.0425; **&lt;0.0001.</i></p

Plot of gender ratio by six birth decades in MS patients from Northern and Southern Europe.

<p> <i>p-value for trend *0.0426; **&lt;0.0004.</i></p

List of Countries with over one hundred cases, divided into three latitude areas.

<p>List of Countries with over one hundred cases, divided into three latitude areas.</p

Kaplan-Meier survival estimates for first treatment discontinuation by IMD in CIS an early MS.

<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0038661#pone-0038661-g002" target="_blank">Figure 2</a> demonstrates a greater rate of IMD discontinuation in early RRMS and CIS populations prescribed IM IFNbeta-1a and SC IFNbeta-1a as compared with IFNbeta-1b and Glatiramer Acetate.</p